Determining a Regulatory Pathway for your Over-the-Counter (OTC) Drug Product

Website http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500253?expDate=Busivents | Edit Freely

Category seminar; webinar; health; medical; pharma; clinical; drug;

Deadline: April 22, 2014 | Date: April 22, 2014

Venue/Country: 38868 Salmon Ter, Fremont, California, U.S.A

Updated: 2014-03-17 23:07:49 (GMT+9)

Call For Papers - CFP

Description:

Over-the-counter (OTC) drug products are sold directly to consumers without the need of a prescription from a healthcare provider. In the US, these products are regulated by the Food and Drug Administration (FDA). Because of the large number of marketed OTC drug products, FDA reviews the active ingredients and labeling of over 80 therapeutic classes of drugs (e.g., analgesics) instead of individual drug products. This webinar will provide clarification on determining a regulatory pathway to bring your OTC drug product to market.

Why Should you Attend:

OTC drug products are vital tothe health care of America. Regulatory pathways for OTC products include utilizing the monograph system or gaining approval through the FDA New Drug Application (NDA) process. The Division of Nonprescription Regulation Development (DNRD) in the Office of Drug Evaluation is responsible for the development of OTC drug monographs. Data presented to support the safety and efficacy of different active ingredients in a particular drug monograph is reviewed by the appropriate scientific personnel. Although DNRD is considered to be the lead division in the development of an OTC drug monograph, reviewers (e.g., medical officers, statisticians, pharmacologists) from multiple divisions within the Office of New Drugs (OND) are involved. It is important to note that if a drug cannot comply with the drug monograph, an approved NDA is necessary before the drug product may be marketed.

Sponsors seeking to market its product OTC, either as a new NDA or a switch from a prescription product, must apply to the Division of Nonprescription Clinical Evaluation (DNCE) in the Office of Drug Evaluation. After the sponsor submits an NDA, DNCE reviews the consumer studies, the post marketing safety data, the OTC labeling, and any regulatory issues. Additional input is obtained from other disciplines outside of DNCE, including, clinical pharmacology, statistics, and chemistry.

Navigating these OTC regulatory routes can be formidable. It is imperative to have a clear understanding of the regulations involved to determine the best pathway for your OTC product.Upon completion of this session, you will have a better understanding of how OTC drug products are regulated by FDA and will know the regulatory pathways (monograph and NDA), labeling and marketing requirements, and potential enforcement risks.

Learning Objectives:

Have a much better understanding of how OTC drug products are regulated by FDA

Know the regulatory pathways (monograph and NDA), labeling and marketing requirements, and potential enforcement risks

Objectives of the Presentation:

Overview of FDA OTC drug product regulation

Utilizing the OTC monograph system as a regulatory pathway

Following the NDA route as a regulatory pathway

Direct to OTC

Rx-to-OTC Switch

Monograph Deviation

Generic

OTC labeling and marketing considerations

Potential FDA enforcement risks

Who can Benefit:

This webinar will provide valuable assistance to:

Regulatory Affairs professionals

Project Managers

QA & QC Managers

OTC Drug Manufacturers

Consultants

Any individuals interested in the OTC drug industry

Quick View

http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500253?expDate=Busivents